Diabetes Drugs Including GLP-1 Agonists May Protect Against Respiratory Diseases in Large Meta-Analysis | Research

The takeaway

In a meta-analysis of 202,727 participants, SGLT2 inhibitors showed the strongest respiratory protection across six lung conditions, while GLP-1 receptor agonists reduced pneumonia, respiratory failure, and asthma risk specifically in obese populations.

202,727 participants
Across 27 trials, novel diabetes drugs showed distinct respiratory profiles — SGLT2 inhibitors protective, GLP-1 RAs beneficial in obesity, DPP-4 inhibitors potentially harmful for asthma

What the researchers found

Across 27 RCTs with 202,727 participants:

**SGLT2 inhibitors** reduced risk of:

- Pneumonia: OR 0.84 (16% reduction)

- Bronchitis: OR 0.59 (41% reduction)

- COPD: OR 0.76 (24% reduction)

- Pulmonary edema: OR 0.51 (49% reduction)

- Respiratory failure: OR 0.77 (23% reduction)

- Asthma: OR 0.55 (45% reduction)

**GLP-1 receptor agonists** were neutral in T2DM but reduced pneumonia, respiratory failure, and asthma risk in obese populations.

**DPP-4 inhibitors** were largely neutral but increased asthma risk (OR 1.70, 70% increase).

SGLT2 inhibitor benefits appeared largely independent of diabetes status.

Why it matters

This is the first comprehensive meta-analysis comparing three major diabetes drug classes for respiratory outcomes. The finding that GLP-1 RAs reduce respiratory disease risk specifically in obese populations is particularly relevant given the surging use of these peptide drugs for weight loss. It suggests that the lung benefits may be mediated by weight reduction or anti-inflammatory effects associated with GLP-1 signaling. The DPP-4 inhibitor asthma warning is also clinically important.

How the study worked

Systematic review and meta-analysis of 27 large randomized controlled trials, prospectively registered in PROSPERO. Both pairwise and network meta-analyses were performed to compare SGLT2 inhibitors, GLP-1 RAs, and DPP-4 inhibitors against placebo. Prespecified respiratory outcomes included pneumonia, bronchitis, COPD, pulmonary edema, pulmonary embolism, respiratory failure, and asthma. Subgroup analyses examined effects by diabetes status and obesity.

What this study cannot tell us

The authors explicitly state these findings are hypothesis-generating and require validation. Respiratory outcomes were secondary endpoints in the included trials — none were designed to study lung diseases primarily. The distinction between GLP-1 RA effects in diabetic vs. obese populations may reflect differences in trial design rather than true biological differences. The DPP-4 inhibitor asthma finding is based on relatively few events and wide confidence intervals.

How to read the evidence

This is a well-conducted meta-analysis of 27 randomized controlled trials with prospective PROSPERO registration. The massive sample size provides strong statistical power. However, respiratory outcomes were secondary in the source trials, and the authors correctly note these findings are hypothesis-generating. The GRADE certainty varies by outcome.

When this study was published

Published in 2025, this is a very recent meta-analysis incorporating data from the latest cardiovascular and metabolic outcome trials. It represents the most comprehensive assessment of diabetes drugs and respiratory outcomes to date.

The bigger picture

The expanding therapeutic reach of diabetes drugs continues to surprise. Just as GLP-1 drugs proved to protect the heart and kidneys, this analysis suggests respiratory protection may be another secondary benefit — particularly in the obese population increasingly being treated with these peptide drugs. The contrast between GLP-1 RAs (modest respiratory benefit) and DPP-4 inhibitors (potential asthma risk) is notable given that both drug classes act on the incretin peptide system.

Questions still open

Is the GLP-1 RA respiratory benefit in obese populations mediated by weight loss, anti-inflammatory effects, or both?
Should patients with asthma avoid DPP-4 inhibitors in favor of GLP-1 RAs or SGLT2 inhibitors for diabetes management?
Would dedicated clinical trials of SGLT2 inhibitors in patients with COPD or other lung diseases confirm these protective effects?

Common questions

Can GLP-1 drugs like semaglutide help my lungs?

This meta-analysis found that GLP-1 receptor agonists reduced the risk of pneumonia, respiratory failure, and asthma in obese populations. The benefit may come from the weight loss these drugs produce, which reduces strain on the respiratory system, or from direct anti-inflammatory effects. However, in diabetic populations overall, GLP-1 drugs were neutral for respiratory outcomes. If you're obese and have respiratory concerns, GLP-1 drugs may offer added lung benefits.

Should I be concerned about DPP-4 inhibitors and asthma?

The meta-analysis found a 70% increased asthma risk with DPP-4 inhibitors (like sitagliptin and saxagliptin). While the authors note this finding needs confirmation, it's worth discussing with your doctor if you have asthma and are taking a DPP-4 inhibitor. Alternative diabetes drugs like SGLT2 inhibitors or GLP-1 receptor agonists showed no asthma risk and may be better options.

Read the original research

Novel antidiabetic agents and the risk of respiratory diseases: a systematic review and meta-analysis of 27 randomized controlled trials.

Frontiers in medicine, 12, 1721311

View on PubMed ↗Publisher’s paper ↗

Citation

Yu, Zhexuan; Gu, Bingyan; Zhang, Junyao; Jin, Weifeng; Wan, Haitong; Jin, Wei. (2025). Novel antidiabetic agents and the risk of respiratory diseases: a systematic review and meta-analysis of 27 randomized controlled trials.. Frontiers in medicine, 12, 1721311. https://doi.org/10.3389/fmed.2025.1721311